This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Ovarian Cancer
  • /
  • Treatment of epithelial ovarian cancer
Journal

Treatment of epithelial ovarian cancer

Read time: 1 mins
Published:8th Nov 2020
Author: Kuroki L, Guntupalli SR.
Source: The BMJ
Availability: Free full text
Ref.:BMJ. 2020 Nov 9;371:m3773.
DOI:10.1136/bmj.m3773
Treatment of epithelial ovarian cancer


Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease process. An integrated approach with gynecologic oncologists as well as medical oncologists, pathologists, and radiologists is of paramount importance to improving outcomes. Surgical cytoreduction to R0 is the mainstay of treatment, followed by adjuvant chemotherapy. Genetic testing for gene mutations that affect treatment is the standard of care for all women with epithelial ovarian cancer. Nearly all women will have a recurrence, and the treatment of recurrent ovarian cancer continues to be nuanced and requires extensive review of up to date modalities that balance efficacy with the patient’s quality of life. Maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous recombination deficiency is becoming more widely used in the treatment of ovarian cancer, and the advancement of immunotherapy is further revolutionizing treatment targets.


Read abstract on library site Access full article